Funds Benchmark
Funds in our coverage with Amgen Inc among their ten largest positions, with about £2.4B of those funds’ assets in it. FE fundinfo data, to 31 Oct 2026.
| 5Y | Volatility | Quartile | ||||||
|---|---|---|---|---|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETFBlackRock | Passive | 7.83% | +52.3% | Pro | Pro | 0.35% | £35.8M | Free account |
| iShares Biotechnology ETFBlackRock | Passive | 7.82% | +48.0% | Pro | Pro | 0.45% | n/a | Free account |
| Amplify CWP Enhanced Dividend Income ETFAmplify ETF Trust | Passive | 5.50% | +14.7% | Pro | Pro | n/a | n/a | Free account |
| Dow 30 Covered Call & Growth ETFGlobal X Funds | Passive | 4.95% | n/a | Pro | Pro | n/a | n/a | Free account |
| iShares Dow Jones Industrial Average UCITS ETFBlackRock | Passive | 4.90% | +7.3% | Pro | Pro | 0.33% | £1.4B | Free account |
| Biotechnology FundPolar Capital | Active | 4.86% | n/a | Pro | Pro | 1.07% | £2.9B | Free account |
| State Street SPDR Dow Jones Industrial Average ETF TrustSPDR ETFs | Passive | 4.80% | +11.9% | Pro | Pro | 0.16% | n/a | Free account |
| Franklin Biotechnology Discovery FundFranklin Templeton | Active | 4.67% | +17.3% | Pro | Pro | 1.81% | £1.6B | Free account |
| Ultra Nasdaq BiotechnologyProShares | Not classified | 4.48% | +96.6% | Pro | Pro | n/a | n/a | Free account |
| Dow 30 Covered Call ETFGlobal X Funds | Passive | 4.42% | +12.1% | Pro | Pro | n/a | n/a | Free account |
| Bellevue Sustainable HealthcareBellevue Asset Management | Active | 4.30% | +7.2% | Pro | Pro | 2.18% | £55.1M | Free account |
| Candriam Equities L BiotechnologyCandriam | Active | 4.15% | +21.0% | Pro | Pro | 2.34% | £1.5B | Free account |
| U.S. Strategic Dividend ETFFederated Hermes International | Passive | 3.80% | +18.8% | Pro | Pro | n/a | n/a | Free account |
| iShares S&P 500 Health Care Sector UCITS ETFBlackRock | Passive | 3.73% | +28.3% | Pro | Pro | 0.15% | £2.2B | Free account |
| Xtrackers MSCI USA Health Care UCITS ETFDWS | Passive | 3.73% | +22.2% | Pro | Pro | 0.12% | £661.1M | Free account |
| State Street Health Care Select Sector SPDR ETFSPDR ETFs | Passive | 3.72% | +27.8% | Pro | Pro | 0.08% | £31.2B | Free account |
| iShares U.S. Healthcare ETFBlackRock | Passive | 3.58% | +25.6% | Pro | Pro | 0.44% | n/a | Free account |
| First Trust NYSE® Arca® Biotechnology Index FundFirst Trust | Passive | 3.54% | +53.4% | Pro | Pro | n/a | n/a | Free account |
| Core Alternative ETFCore Alternative Capital | Passive | 3.51% | −1.9% | Pro | Pro | n/a | n/a | Free account |
| Pru M&G Global BasicsPru | Not classified | 3.50% | n/a | Pro | Pro | n/a | £95K | Free account |
| First Trust Dow 30 Equal Weight ETFFirst Trust | Passive | 3.49% | +14.0% | Pro | Pro | n/a | n/a | Free account |
| BiotechPictet | Active | 3.37% | +20.9% | Pro | Pro | 2.70% | £1.8B | Free account |
| World Healthscience FundBlackRock | Active | 3.32% | +19.8% | Pro | Pro | 1.81% | £10.4B | Free account |
| First Trust Nasdaq Pharmaceuticals ETFFirst Trust | Passive | 3.18% | +48.4% | Pro | Pro | n/a | n/a | Free account |
| Fidelity MSCI Health Care Index ETFFidelity | Passive | 3.00% | +28.1% | Pro | Pro | n/a | n/a | Free account |
| Legal & General Global Health and Pharmaceuticals Index TrustLegal & General | Passive | 2.80% | +19.2% | Pro | Pro | 0.69% | £1.1B | Free account |
| Xtrackers MSCI World Health Care UCITS ETFDWS | Passive | 2.73% | +20.7% | Pro | Pro | 0.25% | £2.8B | Free account |
| Global Equity ResponsibleAmundi | Active | 2.66% | +0.3% | Pro | Pro | 2.08% | £2.0B | Free account |
| iShares MSCI World Health Care Sector Advanced UCITS ETFBlackRock | Passive | 2.37% | +18.1% | Pro | Pro | 0.18% | £718.2M | Free account |
| VanEck Global Healthcare Leaders ETFVanEck | Passive | 2.20% | +12.2% | Pro | Pro | 0.45% | n/a | Free account |
| State Street SPDR S&P Biotech ETFSPDR ETFs | Passive | 1.55% | +36.2% | Pro | Pro | 0.35% | £8.1B | Free account |
| Global X S&P Biotech ETFGlobal X ETFs | Passive | 1.55% | +60.5% | Pro | Pro | 0.45% | n/a | Free account |
| Capital Group Global Corporate Bond Fund (LUX)Capital Group | Active | 1.50% | −2.7% | Pro | Pro | 0.50% | £5.0B | Free account |
| BNY Mellon Global Credit FundBNY | Active | 0.63% | n/a | Pro | Pro | 0.08% | £2.4B | Free account |
Weight is the share of each fund in this company. Returns are GBP, to month end. FE quartile compares a fund with its FE sector over the same year. Fund size is in GBP. Source: FE fundinfo. Past performance is not a reliable guide to future returns.
The Dow Jones fell 1,833 points (3.44%) to close at 51,523 on November 6, led by declines in Nvidia (-9.23%), Cisco (-7.62%), and Goldman Sachs (-6.42%) as chip concerns persisted.
US midterm elections took place with broader market implications amid uncertainty about fiscal policy and geopolitical developments including Iran war impacts.
Early projections pointed to a Democratic victory in the US midterm elections, with Democrats gaining control of Congress. This reduced political uncertainty regarding the Trump administration's fiscal policy.
The Dow Jones jumped 1,569 points (3.03%) to 53,356, the S&P 500 added 1.58% to 7,688, and the Nasdaq gained 1.44% on November 4 following Democratic election victory and falling energy prices.
Private sector employment increased by 86,000 jobs in October, exceeding market expectations of 69,000 and matching September's revised gain.
Democrats secured control of both the Senate and House in the November 3, 2026 midterm elections, reducing geopolitical conflict uncertainty and leading to sharp market rallies, particularly in sectors benefiting from...
Available job positions rose 333,000 to 7.52 million in September, exceeding all economist estimates and signaling firmer demand for workers heading into Q4.
The Nasdaq Composite dropped 2% on Friday with the S&P 500 down 0.9% and Dow down 0.6% for the week as investors dumped tech stocks amid AI spending scrutiny and election uncertainty.
The October 2026 employment report showed 182,000 jobs added with unemployment stable at 4.1%, indicating continued labor market strength above breakeven pace.
U.S. stock indices fell on October 29-30, with S&P 500 down 0.91%, Nasdaq sliding 1.4%, amid renewed concerns about the sustainability of the AI trade following disappointing results from major technology companies.
First estimate of third-quarter U.S. GDP and September PCE inflation data released simultaneously, providing key economic growth and pricing information before year-end.
The Federal Reserve announced its rate decision on October 28 at 2:00 PM ET, widely expected to hold rates steady at 3.75%-4.00% following September's 25-basis-point increase, with markets pricing 90% probability of n...
Counts events recorded in our market events log, not news volume. Information only, not advice.
Source: FE fundinfo. Holdings are each fund’s ten largest positions as reported, so a fund can have more of this company than shown or none at all. Returns are GBP to month end unless stated. Past performance is not a reliable guide to future returns. Capital is at risk. Information only, not advice or a recommendation.
Cookie settings
Choose which cookies we may use. Essential cookies are always on because the site needs them to work. Analytics cookies are off until you turn them on. Cookieless page-view signals to Google Analytics are sent before you choose and if you reject; they set no cookies. Read the privacy notice
